Seminars in Hematology
Volume 44, Issue 1 , Pages 32-41 , January 2007

Emerging Infectious Diseases That Threaten the Blood Supply

  • Harvey J. Alter

      Affiliations

    • Infectious Diseases Section and Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD.
    • Corresponding Author InformationAddress correspondence to Harvey J. Alter, MD, Department of Transfusion Medicine, National Institutes of Health, 10 Center Dr, Building 10, Room 1C-711, Bethesda, MD 20892.
    • ,
  • Susan L. Stramer

      Affiliations

    • Scientific Support Office, American Red Cross Holland Laboratory, Rockville, MD.
    • ,
  • Roger Y. Dodd

      Affiliations

    • Scientific Support Office, American Red Cross Holland Laboratory, Rockville, MD.

References 

  1. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973–1978
  2. Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang. 2006;90:157–165
  3. Krause PJ, Lepore T, Sikand VK, Gadbaw J, Burke G, Telford SR, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000;343:1454–1458
  4. Leiby DA, Chung AP, Cable RG, Trouern-Trend J, McCullough J, Homer MJ, et al. Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors. Transfusion. 2002;42:1585–1591
  5. Chagas disease after organ transplantation—United States, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:210–212
  6. Wendel S. Transfusion-transmitted Chagas’ disease. Curr Opin Hematol. 1998;5:406–411
  7. Leiby DA, Herron RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: Impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42:549–555
  8. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion. 2003;43:1007–1017
  9. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236–1245
  10. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451–459
  11. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586–597
  12. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152:257–265
  13. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: Implications for transfusion medicine (Summary of a workshop). Transfusion. 2001;41:130–135
  14. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999;13:194–204
  15. Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, Forghani B, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 2003;43:1260–1268
  16. Dodd RY. Human herpesvirus-8: What (not) to do?. Transfusion. 2005;45:463–465
  17. Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Fowlkes AL, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006;355:1331–1338
  18. Hien TT, de Jong JM, Farrar J. Avian influenza—A challenge to global health care structures. N Engl J Med. 2004;351:2363–2365
  19. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333–340
  20. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis. 1999;180:1763–1770
  21. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis. 2005;11:201–209
  22. Writing Committee of the World Health Organization Consultation on Human Influenza A/H5: Avian influenza A (H5N1) infections in humans. N Engl J Med. 2005;353:1374–1385
  23. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417–421
  24. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–529
  25. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol. 2004;203:733–739
  26. Sowemimo-Coker SO, Pesci S, Andrade F, Kim A, Kascsak RB, Kascsak RJ, et al. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. Vox Sang. 2006;90:265–275
  27. Gregori L, Gurgel PV, Gheorghiu L, Edwardson P, Lathrop JT, et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion. 2006;46:1152–1161
  28. Boneva RS, Grindon AJ, Orton SL, Switzer WM, Shanmugam V, Hussain AI, et al. Simian foamy virus infection in a blood donor. Transfusion. 2002;42:886–891
  29. Alter HJ. New viruses and their relationship to hepatitis. In:  Schinazi RF,  Sommadossi J-P,  Rice CM editor. Frontiers in Viral Hepatitis. The Netherlands: Elsevier; 2003;p. 35–46
  30. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion. 2006;46:731–740
  31. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885
  32. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1335–1341
  33. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol. 2006;19:205–242

PII: S0037-1963(06)00238-1

doi: 10.1053/j.seminhematol.2006.09.016

Seminars in Hematology
Volume 44, Issue 1 , Pages 32-41 , January 2007

Article Tools